BioNTech stock surges 22% on Moderna cancer vaccine win. Why the gains could fade.

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the ...

Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades

Merck (MRK) stock slips as RBC Capital Markets cuts on valuation while Morgan Stanley upgrades on trial data for Moderna ...

What Moderna’s vaccine trial results might mean for the future of cancer care

In addition to melanoma, Moderna and Merck are conducting trials with personalized injections to fight types of bladder, ...
Asianet Newsable on MSN

Merck’s cancer-vaccine trial results surpassed expectations – so, why did RBC downgrade MRK stock?

RBC Capital noted that while the cancer vaccine results exceeded expectations, the stock’s $150 valuation is ‘unprecedented’ ...
WTAP

New vaccine appears to prevent recurrence of the deadliest form of skin cancer

Moderna and Merck say Phase 3 trial results suggest their individualized mRNA vaccine can prevent melanoma from recurring or ...
CNBC

Squawk Box

Monday - Friday, 6:00 - 9:00 AM ET Richard Haass on ECB Lagarde's AI warning to the EU, Iran war latest and U.S.-South Korea relations United States Monday - Friday 6a ET Europe Monday - Friday 13:00 ...